Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older
- You must have been diagnosed with a type of blood cancer called CLL or SLL that has come back or stopped responding to treatment, confirmed using standard diagnostic guidelines
- You must be well enough to carry out basic daily activities, based on a standard health rating scale scored 0 to 2 (confirm with trial site)
- You must have previously received three specific types of cancer treatments: two different types of BTK inhibitor drugs and one BCL-2 inhibitor drug, either given separately or together as part of your treatment history
- If you have SLL, your disease must be measurable on a scan or imaging
- Your liver, kidneys, and bone marrow must be functioning well enough to take part
- You must be willing to sign a consent form showing you understand what the study involves and agree to take part
Who may not be able to join:
- You may not be eligible if you have or are suspected to have a related blood condition called prolymphocytic leukemia or Richter's transformation
- You must not have received another experimental or cancer-fighting treatment within a certain number of days before starting the trial (confirm exact timeframe with trial site)
- You must not have received antibody-based cancer therapy within 4 weeks before the first dose
- You must not have had limited radiation therapy to a small area within 7 days, or wider-field radiation therapy within 28 days, before starting the trial
- You must not have been taking high-dose steroid tablets (more than 20mg of prednisone or similar) within the 7 days before starting the trial, unless used for a scan preparation
- You must not have taken immune-suppressing medications (other than steroids) within the 60 days before starting the trial
- You must not have previously been treated with a specific type of drug called a BTK degrader
- You must not have had CAR T-cell therapy or a stem cell transplant within the 90 days before joining the trial
- You must not have had a blood clot, stroke, or bleeding in the brain within the 6 months before starting the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nurix Study Director, Nurix Therapeutics, Inc.
Phone: 415-417-3418
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.